Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|September 6, 2022
Rheumatoid Arthritis Quiz: RA Treatment During Pregnancy
Author(s)Ingrid Torjesen
Can women with rheumatoid arthritis (RA) continue their treatment if they become pregnant or should they stop or change therapy to protect their unborn child? Test your knowledge with this quiz.
Advertisement
What proportion of women with RA discontinue disease‐modifying antirheumatic drugs (DMARDs) while pregnant?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement